Inventiva SA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 123
- Market Cap
- -
Lanifibranor Shows Promise in Metabolic Liver Disease Treatment, Phase III Results Expected 2026
• Recent proof-of-concept study demonstrates Lanifibranor's significant efficacy in improving insulin sensitivity and reducing hepatic fat in MASLD patients with type 2 diabetes.
• H.C. Wainwright maintains Buy rating for Inventiva with $13 price target, citing strong potential for Lanifibranor in treating MASH fibrosis.
• Pivotal NATiV3 trial results anticipated in 2026, potentially leading to accelerated approval for MASH fibrosis treatment by end of 2027.
© Copyright 2025. All Rights Reserved by MedPath